TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00850824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker home visits
Description: Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker home visits
Description: Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
Study: NCT02768012

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness-based cognitive therapy
Description: Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
Study: NCT03733795

Intervention type: OTHER
Intervention: TCD
Description: Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.

Intervention type: OTHER
Intervention: TCD
Description: Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
Study: NCT01341132

Intervention type: PROCEDURE
Intervention: MRI Scan of the Liver enhanced with Eovist
Description: 10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
Study: NCT03418610

Intervention type: DRUG
Group type: OTHER
Intervention: Azelaic Acid foam 15%
Description: mild to moderate rosacea
Study: NCT04473703

Intervention type: DRUG
Intervention: renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
Description: Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
Study: NCT00284752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
Study: NCT00667316

Intervention type: BEHAVIORAL
Intervention: Set of questionnaires (respondent)
Description: A set of questionnaires to determine risk factors for sick leave due to low back pain.
Study: NCT03948542

Intervention type: OTHER
Intervention: Outcome
Description: Nerve Recovery~* NCV~* Funcional assessment
Study: NCT02993094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
Study: NCT05254392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital BP monitor (Chidalex®)
Description: Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
Study: NCT03738709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Falls prevention and education giving a demonstration of the usage of technical assistance.
Description: * Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls prevention and education giving a demonstration of the usage of technical assistance.
Description: * Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours.
Study: NCT01981603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: navigator
Study: NCT01299194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATORVASTATIN
Description: 80mg once daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATORVASTATIN
Description: 80mg once daily for 3 months
Study: NCT01477710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hold mask
Description: The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strap Mask
Description: The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway
Description: The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
Study: NCT02739763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoite (PfSPZ)
Description: Plasmodium falciparum sporozoites
Study: NCT02431780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANSeR Software System
Description: ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
Study: NCT04756999

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: massage therapy
Description: Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
Study: NCT03733795

Intervention type: OTHER
Intervention: TCD
Description: Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
Study: NCT03409705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skate Skin group
Description: 2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
Study: NCT02067169

Intervention type: BIOLOGICAL
Intervention: CMV Infection
Description: Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
Study: NCT04250870

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Senior Fitness Test
Description: Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Senior Fitness Test
Description: Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair.
Study: NCT02877615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 44819 150 mg twice a day
Description: One sachet of S 44819 150 mg and one sachet of placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 44819 300 mg twice a day
Description: Two sachets of S 44819 150 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sachets of placebo twice a day
Study: NCT03409705

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 2,000 mg of starch was orally administered per day for 12 weeks.
Study: NCT04654169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IAI
Description: Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided IAI
Description: Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SSNB
Description: Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
Study: NCT03447210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Partner Services
Description: Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
Study: NCT02351063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changes of heart failure medications
Description: Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
Study: NCT03789136

Intervention type: OTHER
Intervention: Not applicable, observational study
Description: Not applicable, observational study

Intervention type: OTHER
Intervention: Not applicable, observational study
Description: Not applicable, observational study

Intervention type: OTHER
Intervention: Not applicable, observational study
Description: Not applicable, observational study

Intervention type: OTHER
Intervention: Not applicable, observational study
Description: Not applicable, observational study
Study: NCT02756962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: * Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: * Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment
Study: NCT03449680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Articular Branch Block
Description: Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Subcutaneous injection of 1ml normal sterile saline
Study: NCT04651413

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR Value
Description: Data collection and interpretation
Study: NCT04047186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
Study: NCT02907255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oximetry monitor
Description: Wireless respiratory monitoring system
Study: NCT01649401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard nebulizer
Description: Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI LC Sprint Sp nebulizer
Description: Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany
Study: NCT01178216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
Study: NCT01934335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02612259

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TRYPTOPHAN
Description: at the dose of 3,5 m/kg/ day divided in two capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: at the dose of 3,5 m/kg/ day divided in two capsules
Study: NCT02756962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch skin biopsy
Description: * The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch skin biopsy
Description: * The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinSeq
Description: Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinSeq
Description: Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
Study: NCT00873223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
Study: NCT00948987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg enteric coated single dose p.o.
Study: NCT03692065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 MG
Description: Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 MG
Description: Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
Study: NCT02612324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pono Choices
Description: Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
Study: NCT03423030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 Formulation
Description: PBTZ169 Formulation supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 Formulation
Description: PBTZ169 Formulation supplied as powder for oral solution
Study: NCT04436250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine Low dose
Description: The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine High dose
Description: The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
Study: NCT03206086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
Study: NCT02397096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine, Tenofovir, Lamivudine
Description: Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine
Description: Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Description: Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Description: Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of cobicistat-boosted elvitegravir
Description: Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of cobicistat-boosted elvitegravir
Description: Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Study: NCT03423030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 Formulation
Description: PBTZ169 Formulation supplied as powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 Formulation
Description: PBTZ169 Formulation supplied as powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study: NCT02397096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Study: NCT06099548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Elevate™ System
Description: The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.